Gene Silencing News and Research

RSS

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam Pharmaceuticals, Inc. and Tekmira Pharmaceuticals Corporation announced today that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.

6 Aug 2009

Epigenetic alterations may serve as markers for chronic leukemia

A new study shows that certain genes are turned off early, before clinical signs of the disease appear, in the development of chronic leukemia.

5 Aug 2009

Nanoparticle Trojan horse for ovarian cancer

In a feat of trickery, Dartmouth Medical School immunologists have devised a Trojan horse to help overcome ovarian cancer, unleashing a surprise killer in the surroundings of a hard-to-treat tumor.

19 Jul 2009

MicroRNAs grease the cell's circadian clockwork

Most of our cells possess an internal clock, a group of genes displaying a cyclic expression pattern that reaches a peak once a day. A large number of circadian genes are expressed by organs such as the liver, whose activity needs to be precisely regulated over the course of the day.

31 May 2009

New system to deliver siRNA into primary cells

In technology that promises to one day allow drug delivery to be tailored to an individual patient and a particular cancer tumor, researchers at the University of California, San Diego School of Medicine, have developed an efficient system for delivering siRNA into primary cells.

17 May 2009

Oral delivery system for RNAi therapeutics

Researchers at the University of Massachusetts Medical School (UMMS) report on a novel approach to the delivery of small bits of genetic material in order to silence genes using "RNA interference"-and in the process, discovered a potent method of suppressing inflammation in mice similar to what occurs in a range of human diseases.

30 Apr 2009

New nucleotide could revolutionize epigenetics

Anyone who studied a little genetics in high school has heard of adenine, thymine, guanine and cytosine - the A,T,G and C that make up the DNA code.

16 Apr 2009

RNA interference can be used to silence genes selectively - potential for Huntington's disease therapy

Howard Hughes Medical Institute researchers have designed tiny RNA molecules that shut off the gene that causes Huntington's disease without damaging that gene's healthy counterpart, which maintains the health and vitality of neurons.

12 Apr 2009

Molecule called miR-29b could be a potent treatment for acute myeloid leukemia

A new study by Ohio State University cancer researchers shows that boosting the level of a molecule called miR-29b in acute myeloid leukemia (AML) cells can reverse gene changes that trap the cells in an immature, fast growing state of development.

5 Apr 2009

RNA World: a new frontier in biomedical research

Research into RNA, a molecule found in every cell of our bodies, could lead to remarkable advances in the treatment of diseases such as cancer and diabetes, a meeting organised by the European Science Foundation was told.

4 Mar 2009

Gold nanoparticles improve gene regulation

Investigators at Northwestern University have found that packing small interfering RNA (siRNA) molecules onto the surface of a gold nanoparticle can protect siRNAs from degradation and increase their ability to regulate genes involved in cancer. As a result of this discovery, cancer researchers have at their disposal a relatively straightforward method of delivering these potent gene-regulating agents into targeted cells.

23 Feb 2009

Novel gene silencing platform

A team of researchers led by Rutgers' Samuel Gunderson has developed a novel gene silencing platform with very significant improvements over existing RNAi approaches.

16 Feb 2009

Novel gene silencing platform

A team of researchers led by Rutgers' Samuel Gunderson has developed a novel gene silencing platform with very significant improvements over existing RNAi approaches.

8 Feb 2009

Microfluidic devices capture and analyze single cancer cells

One of the grand goals in nanotechnology is to develop a single microfluidic device that integrates all of the components needed to perform polymerase chain reaction (PCR)-based nucleic acid analyses. Experts predict that such a device would enable researchers to develop rapid assays for cancer and other life-threatening diseases while a patient is in the doctor's office.

18 Jan 2009

Biologist finds plant polymerases IV and V are really variants of polymerase II

It's a little like finding out that Superman is actually Clark Kent. A team of biologists at Washington University in St. Louis has discovered that two vital cellular components, nuclear RNA Polymerases IV and V (Pol IV and V), found only in plants, are actually specialized forms of RNA Polymerase II, an essential enzyme of all eukaryotic organisms, including humans.

6 Jan 2009

Levels of two proteins impact survival in ovarian cancer

Levels of two proteins in a woman's ovarian cancer are strongly associated with her likelihood of survival, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Dec. 18 issue of the New England Journal of Medicine.

17 Dec 2008

RNA interference can facilitate vaccine development

Pharmaceutical companies and universities are racing to develop drugs that use the gene silencing mechanism known as RNA interference to treat a host of diseases.

10 Dec 2008

Breakthrough in understanding the phenomenon of nucleolar dominance

Since the machinery involved in nucleolar dominance is some of the same machinery that can go haywire in diseases such as cancer, Pikaard and his collaborators' research may have important implications for applied medical research.

5 Dec 2008

Discovery of groundbreaking technique for body to accept gene therapy

Researchers at Columbia University Medical Center and the State University of New York at Stony Brook (SUNY) have developed a groundbreaking technique to sneak therapeutic genes past the body's defenses, possibly clearing one of the largest hurdles to realizing the potentials of medically altering a patient's DNA.

5 Dec 2008